36011-19-5
Chemical Structure
Cytochalasin E
- CAS No.: 36011-19-5
- Formula:C28H33NO7
- Molecular Weight:495.56
IUPAC Name: (1E,4S,6R,7E,11aS,14S,14aS,15S,15aR,16aS,16bS)-14-benzyl-6-hydroxy-4,6,15,15a-tetramethyl-3,13,14,14a,15,15a,16a,16b-octahydro-[1,3]dioxacyclotridecino[4,5-d]oxireno[2,3-f]isoindole-5,10,12(4H,6H)-trione
InChIKey: LAJXCUNOQSHRJO-ZYGJITOWSA-N
SMILES: O=C1[C@]2(O3)[C@]([C@@H]([C@](O4)(C)[C@@H]4[C@]2([H])/C=C/C[C@@H](C([C@](C)(O)/C=C/OC3=O)=O)C)C)([H])[C@H](CC5=CC=CC=C5)N1
Biological Activity: Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. Cytochalasin E is a potent actin depolymerization agent, and it binds and caps the barbed end of actin filaments to prevent actin elongation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cytochalasin E | 99.90% | Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. Cytochalasin E is a potent actin depolymerization agent, and it binds and caps the barbed end of actin filaments to prevent actin elongation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cytochalasin E (Standard) | ≥98% | Antazoline (phosphate) (Standard) is the analytical standard of Antazoline (phosphate). This product is intended for research and analytical applications. Antazoline phosphate is an H1 receptor antagonist that affects the activity of the central nervous system, has a potent antiarrhythmic effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Udagawa T, et al. Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesisand tumor growth. J Pharmacol Exp Ther. 2000 Aug;294(2):421-7. [Content Brief]
- [2]. Lu QY, et al. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenicmodel. Clin Cancer Res. 2005 Feb 15;11(4):1675-83. [Content Brief]
